Please enter the email address you used to register, then we will send you a link to choose a new password
Soligenix shares surged on heavy volume, following an interim update on the extended Hybryte treatment study.
SNGX: 142% | Soligenix shares are trading higher after the company announced interim results for extended HyBryte treatment in ...
"In the Phase 3 FLASH study, HyBryte™ was shown to be efficacious with a promising safety profile. With limited treatment o...
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and comm...
https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_06142024_SNGX_Bautz.pdf
https://ppubs.uspto.gov/pubwebapp/external.html?q=(20240189413).pn